PubMed Health⌕ Search

Biomedical subjects

G Mathe

Publications and source records attributed to G Mathe.

At least 55 records · Page 3Linked to original sources
PubMed1980

Study of the effect of single or multiple doses of BCG on antibody-dependent cellular cytotoxicity.

The in vivo effects of BCG were studied on antibody-dependent cellular cytotoxicity (ADCC) using an assay in which the effectors were spleen cells of BCG-treated mice, and the targets antibody-coated chicken red blood cells (CRBC). In the study of the time course of action, an increased ADCC-activity was observed starting at day 10 with a maximum (four-fold augmentation) at day 14 after BCG treatment. The nature of the effector cell was investigated: in normal mice the activity was found in two cell populations, i.e. macrophages and theta-negative (theta-) nylon-adherent spleen cells. A BCG treatment increased the ADCC activity of macrophages of theta- nylon-adherent spleen cells and induced a population of theta- nylon-non-adherent spleen cells. In old mice, the effects of BCG were compared after a weekly long-term (6 months) treatment and after administration of a single dose. It was concluded that ADCC is higher in old mice than in young mice and can be further increased by treatment with a single dose of BCG in contrast with the long-term treatment which impaired this immune reaction.

Aging↗
PubMed1979

Bone marrow transplantation (1958-1978) : conditioning and graft-versus-host disease, indications in aplasias and leukemias.

Bone marrow transplantation (BMT), which stimulated great hope for treatment of aplasias and leukemias in 1958 following our first success in grafting this tissue, is, after a long period of study and development, experiencing renewed interest since it is now possible to obtain, in case of transplantation with genotypically matched sibling donors, 70% long survival (cures ?) in aplasia (under the condition that the recipient is not sensitized by previous transfusions) and in leukemia (under the condition that the recipient is transplanted in a period of remission and is not sensitized by transfusions). When the patient does not possess any genotypically matched donor, a trial of incompatible bone marrow transplantation after conditioning with antilymphocyte serum is reasonable, since we have obtained good, although unexplained, results with this method, which should be pursued. In any case, these transplants must be done in intensive care units in hemato-oncology departments.

Anemia, Aplastic↗
PubMed1979

[Ultrastructural study of cardiotoxicity and skin alterations in the golden hamster after treatment with 8 different anthracyclines].

Golden hamsters were submitted to i.p. administration during 4 weeks of 8 anthracyclines, adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4'-epi-adriamycin (eADM), adriamycin hydrochloride (ADMh), rubidazon (RBZ), aclacinomycin (ACM) and AD32, at doses equivalent to 3/4 of those which are optimally oncostatic on murine L1210 leukemia. The comparative study of the mortality, the electron microscopic (EM) alterations of the myocardium, and the light microscopic (EM) alterations of the myocardium, and the light microscopic (LM) lesions of the skin, show that ACM and AD32 are the least toxic drugs. EM detected almost no early lesions of myocardium in ACM treated animals, but, after 4 week's treatment, severe cardiac alterations appeared which, like those after AD32 treatment, are non lethal and reversible. Similarly. LM revealed no histologic changes in the skin following ACM and AD32 administrations, but pathologic alterations, atrophy and alopecia, were observed in animals receiving all other drugs.

Animals↗
PubMed1978

Decreased microviscosity of membrane lipids in leukemic cells: two possible mechanisms.

Steady-state fluorescence polarization studies with the fluorescent lipid probe 1,6-diphenyl 1,3,5-hexatriene were done to determine the degree of microviscosity of cellular membrane lipids and serum lipoproteins in human normal donors and leukemic patients. The results show a marked decrease in microviscosity of cellular membrane lipids in both intact lymphocytes and isolated cellular plasma membranes obtained from leukemic patients in clinical relapse as compared to intact lymphocytes and isolated cellular plasma membranes obtained from normal donors and leukemic patients in complete clinical remission. Concomitant to these dynamic changes in cellular membrane lipids, the degree of microviscosity of lipids in the blood serum of leukemic patients in clinical relapse is markedly reduced as compared to serum obtained from normal donors and leukemic patients in complete clinical remission. Moreover, an in vitro incubation of leukemic lymphocytes with normal low density lipoproteins results in an increased microviscosity of cellular membrane lipids. In addition to the interrelation between cellular membrane lipids and serum lipoproteins, plasma membrane vesicles with a high degree of lipid microviscosity were isolated from the blood serum and pleural effusion of leukemic patients in clinical relapse. Such membrane vesicles could not be detected in normal serum. Therefore, we suggest that the two major mechanisms associated with the decreased microviscosity of membrane lipids in human leukemic cells are an abnormal exchange in lipids between the leukemic cell surface membrane and leukemic serum lipoproteins and an exfoliation of plasma membrane vesicles with a high degree of microviscosity from the cell surface of leukemic cells.

Cell Membrane↗
PubMed1977

Graft-versus-host reaction. Influence of genetic background in donor-recipient pairs incompatible for major histocompatibility complex (MHC).

In two H-2b anti-H-2d but not in H-2b anti-H2k donor-recipient combinations, graft-versus-host reaction (GVHR) mortality was found to vary as a function of the host's genetic background; the same non-major histocompatibility complex genes and/or antigens which influence GVHR mortality do not influence the intensity of GVHR splenomegaly or the time of skin rejection. In contrast, the severity of GVHR mortality correlates with the intensity of stimulation in mixed lymphocyte culture. The roles of minor histocompatibility (H) antigens and Mls product are discussed.

Animals↗
PubMed1977

Further purification and chemical characterization of the lymphocyte-inhibiting-factor extracted from thymus (LIFT).

A thymic extract which was previously demonstrated to contain a lymphocyte-inhibiting-factor (LIFT) based on its immunosuppressive activity in vivo and its antiproliferative properties on lymphocytes in vitro, has been purified using ultrafiltration procedures. Most of the activity measured by the ability to inhibit DNA synthesis in short term cultures of mouse thymocytes, was recovered in the 10,000-50,000 m. wt fraction (I fraction). In contrast, similar extracts from non-lymphoid organs were always ineffective in decreasing DNA synthesis in thymocytes. The I fraction was also inhibitory of DNA synthesis in mouse spleen cells stimulated by PHA whatever the time at which the fraction was added after the mitogen stimulation. This fraction, as well as the crude thymic extract, was ineffective in decreasing DNA synthesis in non-lymphoid target cells. The I fraction was further purified by Sephadex G50 filtration and DEAE Sephadex chromatography. The active molecule seemed to be a heat resistant basic peptide probably bound to a ribonucleotide moiety.

Animals↗
PubMed1976

Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.

Forty-three patients with inoperable or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of Adriamycin (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (60 mg/m2 for 2 days). These cycles of treatment were repeated as soon as the hematologic restoration was complete. The treatment was well tolerated and the clinical condition of 31 of 43 glioblastoma patients improved during the 2 months after the beginning of the treatment. Six of eight patients with breast cancer metastases, one of 13 with bronchial cancer matastases, and three of nine with other types of cancer metastases also benefitted from the treatment. Examination of the results obtained revealed the following characteristics: 1) This combination had a low degree of efficiency in the treatment of metastases to brain, except for breast cancer metastases; 2) there was no complete correlation between the clinical results observed and the cinegammagraphic developments; 3) the results obtained were similar, independent of the initial localization; and a 6-month median survival period was established, with 10 patients now in a state of apparently complete remission, 180 to 506 days after beginning of the treatment.

Adult↗